Sugi Predict

Sugi Predict / Compounds / SCHEMBL2939874

SCHEMBL2939874

SCHEMBL2939874

CCN(CC)CCOC(=O)Nc1cc(CN2CC(=O)N(c3ccc(S(=O)(=O)C(F)(F)F)cc3)C2=O)ccn1

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 9/20 0.39
▸ PPARD Q03181 2/20 0.37
▸ PPARA Q07869 2/20 0.37
▸ PPARG P37231 1/20 0.34
▸ MMP1 P03956 2/20 0.32
▸ MMP9 P14780 2/20 0.32
▸ MMP13 P45452 2/20 0.32
▸ PKM P14618 1/20 0.31
▸ PIK3C3 Q8NEB9 2/20 0.31
▸ MAPK14 Q16539 1/20 0.31
▸ TAS2R8 Q9NYW2 1/20 0.31
▸ MET P08581 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942840 0.90 IGF1R (0.40) IGF1RPPARDPPARAPPARGPKM
SCHEMBL2941646 0.90 IGF1R (0.42) IGF1RPPARDPPARAPPARGPKM
SCHEMBL2934731 0.88 IGF1R (0.40) IGF1RPPARDPPARAPPARG
SCHEMBL2937370 0.87 IGF1R (0.52) IGF1RPPARDPPARA
SCHEMBL2940499 0.85 IGF1R (0.41) IGF1RPPARDPPARAPPARGTAS2R8
SCHEMBL2938842 0.85 IGF1R (0.49) IGF1RMMP1MMP9MMP13PKM
SCHEMBL2941995 0.85 IGF1R (0.57) IGF1R
SCHEMBL2938006 0.84 IGF1R (0.49) IGF1RPPARDPPARAPPARGPIK3C3
SCHEMBL2938394 0.83 NR3C2 (0.45) IGF1RPPARDPPARA
SCHEMBL3724588 0.82 IGF1R (0.39) IGF1RPPARDPPARAPPARGTAS2R8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885PPARD 3189/4885PPARA 4338/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885PPARD 3572/4885PPARA 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.